FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Tumoral pSMAD2 as a prognostic biomarker in early-stage breast cancer: insights from the randomized SweBCG91RT trial. PMID 40488800 · Breast Cancer Res Treat · 2025-Aug The record describes a biomarker analysis (pSMAD2) of a randomized trial (SweBCG91RT) comparing radiotherapy vs. no radiotherapy after surgery. The intervention is non-drug (radiotherapy), and the primary endpoint is recurrence risk (ipsilateral breast tumor recurrence and all recurrences). While recurrence is a time-to-event endpoint, the study is explicitly a biomarker-focused prognostic analysis (subgroup/secondary) of a trial with a non-drug intervention. It lacks a drug-containing intervention and does not present a primary time-to-event efficacy analysis for a drug. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer. PMID 40484776 · Clin Breast Cancer · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Choice architecture in cascade genetic testing (CHARGE study) for hereditary cancer: Design of a hybrid type I randomized feasibility trial. PMID 40482962 · Contemp Clin Trials · 2025-Aug Record is a clinical trial protocol (ClinicalTrials.gov Identifier: NCT06284330) for a randomized trial of cascade genetic testing in hereditary cancer. It is a non-drug intervention (choice architecture/behavioral) trial, not a drug-containing intervention. The primary outcome is a testing rate (binary), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.) or a Kaplan-Meier analysis. The record describes the study design but does not report results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Response to: Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. PMID 40465199 · Adv Ther · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. PMID 40465198 · Adv Ther · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study. PMID 40461387 · Clin Breast Cancer · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. PMID 40461383 · Ann Oncol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| [68Ga]Ga-PSMA-11 PET/CT and [18F]Fluorocholine PET/CT in Assessment and Clinical Decision Making of Recurrent Prostate Cancer: A Prospective Crossover Trial. PMID 40437314 · Mol Imaging Biol · 2025-Aug The study is a prospective randomized crossover trial in oncology (human prostate cancer) with original results. However, it is excluded because it does not meet the criteria for a Phase III/IIIb or Phase II/III randomized trial (phase is not specified, but the intervention is diagnostic imaging, not a therapeutic drug) and it lacks a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial. PMID 40437173 · Leukemia · 2025-Aug The record describes a randomized, oncology, human, drug-intervention trial that reports time-to-event efficacy endpoints (DFS, OS). However, the provided metadata does not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. The abstract does not mention the phase, and the publication types or MeSH terms do not include a definitive phase designation. Therefore, eligibility cannot be determined without this critical criterion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. PMID 40425844 · Nat Med · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The role of PET/CT in peripheral T-cell lymphoma: Results from the PET/CT substudy of the UK NCRI phase 2 CHEMO-T trial. PMID 40419413 · Br J Haematol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intrafraction motion stability of open vs. closed facemasks in head and neck radiotherapy: Insights from the OPEN phase III trial. PMID 40409364 · Radiother Oncol · 2025-Aug Study is a phase III randomized trial in head and neck cancer, but it compares radiation immobilization devices (facemasks) and reports on technical motion endpoints (intrafraction deviation, PTV margins), not a drug intervention or time-to-event efficacy outcome. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical outcomes of Japanese patients treated with out-of-specification tisagenlecleucel in a phase 3b trial. PMID 40377509 · Cytotherapy · 2025-Aug The study is an oncology, human, Phase IIIb, drug-intervention (tisagenlecleucel) trial with original results, but it is explicitly single-arm (non-randomized) and the reported efficacy endpoint is best response (CR/PR), not a time-to-event outcome. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001. PMID 40361276 · Pediatr Blood Cancer · 2025-Aug The study is an oncology Phase III trial in humans with a drug intervention, but it reports baseline neurocognitive functioning as a secondary/quality-of-life outcome, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analysis). Randomization status is not explicitly established in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Paranasal Sinus and Nasal Cavity Cancers: Systematic Review and Executive Summary of the American Radium Society Appropriate Use Criteria. PMID 40344605 · Head Neck · 2025-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Ixekizumab in Chinese Patients with Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Level. PMID 40343690 · Rheumatol Ther · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk Bladder Cancer. PMID 40340174 · Eur Urol Oncol · 2025-Aug The trial is a randomized, prospective study in oncology (bladder cancer) with results, but it compares surveillance methods (marker-based vs. standard cystoscopy) and does not involve a drug-containing intervention. The primary endpoint is diagnostic accuracy (sensitivity) and resource utilization (number of cystoscopies), not a time-to-event efficacy endpoint. Phase is not explicitly stated as III/IIIb or II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials. PMID 40326221 · BJOG · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of OSPREY Cohort B. PMID 40320701 · Prostate · 2025-Aug This is a subgroup analysis of a prospective Phase II/III diagnostic trial evaluating the performance of a radiopharmaceutical (18F-piflufolastat) for imaging. It is not a randomized therapeutic trial, does not report time-to-event efficacy outcomes (OS, PFS, etc.), and does not evaluate a systemic drug intervention for treatment efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Docetaxel Versus Surveillance in Intermediate- or High-risk Prostate Cancer After Radical Curative Radiotherapy: Final Survival Results from the SPCG-13 Trial. PMID 40312180 · Eur Urol Oncol · 2025-Aug The record meets all criteria except explicit confirmation of a definitive phase (Phase III/IIIb or Phase II/III). The study is oncologic, human, randomized, involves a drug intervention, reports original results for a time-to-event primary endpoint, and is a final report. However, the absence of explicit phase information in the provided metadata prevents a definitive eligibility determination, requiring a null is_eligible status. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase. PMID 40302153 · Clin Pharmacol Ther · 2025-Aug The record describes a pharmacokinetic modeling and simulation study using data from a phase III trial. It does not present original results of a randomized trial with a time-to-event efficacy endpoint (OS, PFS, etc.). The focus is on dosing, PK variability, and exposure confirmation, not on clinical efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotactic Ablative Body Radiotherapy. PMID 40288917 · Eur Urol Oncol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Medical and Nutritional Outcomes Are Similar Among Autologous Transplant Patients on Enteral Nutrition When Compared to Parenteral Nutrition. A Randomized Pilot Study. PMID 40273948 · Eur J Haematol · 2025-Aug The study is a randomized, human oncology trial reporting a time-to-event endpoint (OS). However, it is explicitly a pilot study (likely Phase II or earlier), not a Phase III/IIIb or Phase II/III trial, and the intervention is non-drug (nutritional support). Therefore, it does not meet the core eligibility criteria for inclusion in this digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial. PMID 40258573 · J Thorac Oncol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Surveillance With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of Patients With Stage I-to-III Lung Cancer After Completion of Curative treatment (SUPE_R): A Randomized Controlled Trial. PMID 40258572 · J Thorac Oncol · 2025-Aug The record is a randomized, controlled, oncology trial in humans with time-to-event endpoints (TTR, OS) and reports primary results. However, it does not include a drug-containing intervention; the interventions are surveillance methods ([18F]FDG PET/CT vs. ceCT). Therefore, it fails the mandatory drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial. PMID 40210087 · Ann Oncol · 2025-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Clinical Trial Protocol for ACCURATE: A CCafU-UroCCR Randomized Trial: Three-dimensional Image-guided Robot-assisted Partial Nephrectomy for Renal Complex Tumor (UroCCR 99). PMID 40199643 · Eur Urol Oncol · 2025-Aug 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nodal status in major salivary gland cancer: External validation of a novel N- classification. PMID 40194336 · Eur J Surg Oncol · 2025-Aug This is an observational, external validation study of a novel nodal classification system for salivary gland cancer. It is not a randomized controlled trial, does not involve a drug intervention, and is not a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial. PMID 40120597 · Lancet Infect Dis · 2025-Aug The study is a Phase III randomized trial of an oncology drug (HPV vaccine) with primary results, but its primary endpoint is immunogenicity (non-inferiority of geometric mean antibody concentrations), not a time-to-event efficacy endpoint like overall survival or progression-free survival. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Efficacy of Texture and Color Enhancement Imaging Observation in the Detection of Colorectal Lesions: A Multicenter, Randomized Controlled Trial (deTXIon Study). PMID 40113100 · Gastroenterology · 2025-Aug The study is a randomized, human, oncology-related trial with original results, but it fails on two key eligibility criteria: it is not a drug intervention trial and does not use a time-to-event endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Endoscopic En Bloc vs Piecemeal Resection of Large Colonic Adenomas: Carbon Footprint Post Hoc Analysis of a Randomized Trial. PMID 40049342 · Clin Gastroenterol Hepatol · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cold snare endoscopic mucosal resection versus standard hot technique for large flat nonpedunculated colonic lesions: a randomized controlled trial. PMID 39970943 · Endoscopy · 2025-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Early Oral Nutritional Supplementation in Preventing Weight Loss in Head and Neck Cancer Patients Undergoing Postoperative Radiotherapy or Chemoradiotherapy: A Prospective Randomized Controlled Trial. PMID 39903480 · J Am Nutr Assoc · 2025-Aug The record describes a randomized trial in oncology patients, but the intervention is a nutritional supplement (non-drug) and the primary endpoint is a non-time-to-event measure (weight change). It therefore does not meet the required criteria for a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Enhanced Versus Standard Navigation to Promote Timely Initiation of Adjuvant Radiotherapy for Head and Neck Cancer. PMID 39761486 · JCO Oncol Pract · 2025-Aug The record does not meet the 'drug intervention' criterion, as the intervention is a non-drug patient navigation program, not a pharmacologic agent. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intraoperative Molecular Imaging With Pafolacianine in Resection of Occult Pulmonary Malignancy in the ELUCIDATE Trial. PMID 39442905 · Ann Thorac Surg · 2025-Aug The record describes a Phase III clinical trial in oncology (lung neoplasms) involving a drug (pafolacianine) as an imaging agent. However, the study is not randomized (it is a single-arm imaging study), and the reported endpoints are diagnostic performance metrics (detection rate, PPV, malignancy rate) rather than a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR). The intervention is a diagnostic imaging agent used intraoperatively, not a therapeutic drug intervention with a survival or progression endpoint. Therefore, it does not meet the eligibility criteria for a Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial. PMID 40364136 · J Clin Med · 2025-Apr-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Applicability of ultrasound-guided puncture and laparoscopic cystectomy for ovarian endometriosis cyst: a non-randomized trial. PMID 40307955 · Eur J Med Res · 2025-Apr-30 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial. PMID 40170372 · JNCI Cancer Spectr · 2025-Apr-30 The record is an original article, but it reports a feasibility substudy on patient-reported outcomes collection, not the primary or key secondary efficacy results of the Phase III trial. It lacks a time-to-event efficacy endpoint and is not a randomized comparison. Therefore, it does not meet the eligibility criteria for inclusion in the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. PMID 40295143 · J Immunother Cancer · 2025-Apr-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of oesophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial. PMID 40288803 · BMJ Open · 2025-Apr-27 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial. PMID 40042578 · Jpn J Clin Oncol · 2025-Apr-26 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors. PMID 39987488 · Jpn J Clin Oncol · 2025-Apr-26 This is a record of a clinical trial protocol describing the study design, aims, and endpoints, but it does not report the results of the trial. While the study is randomized, involves chemotherapy, and has overall survival as a primary endpoint, the phase is not explicitly stated in the metadata, and the record is a protocol without results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparison of the inflammatory biomarkers IL- 6, TNF-α, and CRP to predict the effect of nutritional therapy on mortality in medical patients at risk of malnutrition : A secondary analysis of the randomized clinical trial EFFORT. PMID 40275239 · J Inflamm (Lond) · 2025-Apr-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| NEoAdjuvant radiohormonal therapy versus standard of care for oligometastatic prostate cancer (NEAR-TOP): study protocol of a multicenter, open-label, randomised controlled trial. PMID 40275195 · BMC Cancer · 2025-Apr-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma. PMID 40275077 · Commun Med (Lond) · 2025-Apr-24 Cannot confirm eligibility because the trial phase is not specified in the abstract, and the report is a biomarker subgroup analysis of a randomized trial, not the primary efficacy report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy. PMID 40274284 · J Immunother Cancer · 2025-Apr-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| [Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer]. PMID 40268551 · Zhonghua Zhong Liu Za Zhi · 2025-Apr-23 The study is a Phase III randomized oncology trial with a drug intervention, but its primary efficacy endpoint is a pharmacodynamic/biomarker outcome (hormone suppression), not a time-to-event clinical efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study. PMID 39853273 · Blood Adv · 2025-Apr-22 The report is a secondary analysis of a Phase III randomized trial (ALPINE) in human oncology (CLL) with a drug intervention (zanubrutinib vs ibrutinib), but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Instead, it presents mutation data and resistance mechanisms, which is a secondary/biomarker analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial. PMID 39808795 · Blood Adv · 2025-Apr-22 The report is a secondary/biomarker analysis within a Phase III trial. While it includes time-to-event data and HRs, the primary focus is on the prognostic impact of clonal hematopoiesis, not the reporting of the trial's primary or key secondary efficacy results for the drug intervention. Therefore, it does not meet the inclusion criteria for original formal-result reports of the randomized trial's efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies. PMID 39774762 · Blood Adv · 2025-Apr-22 The record describes a Phase III randomized trial of a drug (iptacopan) for paroxysmal nocturnal hemoglobinuria (an oncologic/hematologic malignancy). However, the abstract exclusively reports on patient-reported outcomes of fatigue and quality of life (using FACIT-Fatigue and EORTC QLQ-C30 questionnaires). It does not mention or provide any data on a time-to-event efficacy endpoint such as overall survival, progression-free survival, disease-free survival, or a time-to-event analysis via Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the required criterion for a primary or key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |